Aspyra (OTCMKTS:APYI – Get Free Report) and Schrodinger (NASDAQ:SDGR – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.
Analyst Recommendations
This is a summary of current ratings and target prices for Aspyra and Schrodinger, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aspyra | 0 | 0 | 0 | 0 | 0.00 |
| Schrodinger | 1 | 3 | 4 | 0 | 2.38 |
Schrodinger has a consensus price target of $25.71, indicating a potential upside of 45.61%. Given Schrodinger’s stronger consensus rating and higher probable upside, analysts clearly believe Schrodinger is more favorable than Aspyra.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Aspyra | N/A | N/A | N/A |
| Schrodinger | -68.49% | -48.24% | -24.21% |
Insider & Institutional Ownership
79.1% of Schrodinger shares are held by institutional investors. 23.9% of Aspyra shares are held by company insiders. Comparatively, 21.0% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Aspyra has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Comparatively, Schrodinger has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500.
Earnings & Valuation
This table compares Aspyra and Schrodinger”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aspyra | N/A | N/A | N/A | N/A | N/A |
| Schrodinger | $256.95 million | 5.06 | -$187.12 million | ($2.41) | -7.33 |
Aspyra has higher earnings, but lower revenue than Schrodinger.
About Aspyra
Aspyra Inc. provides health care products and services for the laboratory and imaging marketplaces. It offers engineered workflow solutions that include software, interfaces, hardware, and professional services to various markets comprising specialty labs, reference labs, clinics, hospitals, imaging centers, and orthopedic practices. The company was formerly known as Creative Computer Applications Inc. and changed its name to Aspyra Inc. in November 2005. Aspyra Inc. was founded in 1978 and is headquartered in Jacksonville, Florida.
About Schrodinger
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Receive News & Ratings for Aspyra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspyra and related companies with MarketBeat.com's FREE daily email newsletter.
